| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 06/13/2002 | CA2429769A1 Methods of treatment involving human mda-7 |
| 06/13/2002 | CA2429728A1 Tyrosine kinase inhibitors |
| 06/13/2002 | CA2428097A1 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 06/13/2002 | CA2428092A1 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 06/13/2002 | CA2425396A1 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| 06/12/2002 | EP1213351A2 Nucleic acid enzymes acquiring an activity for cleaving a target RNA by recognising another molecule |
| 06/12/2002 | EP1213348A2 Parasite-derived resistance |
| 06/12/2002 | EP1213300A1 Novel human androgen receptor variants |
| 06/12/2002 | EP1213032A1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| 06/12/2002 | EP1212464A2 Diagnostics and therapeutics for osteoporosis |
| 06/12/2002 | EP1212456A1 Antisense modulation of shp-2 expression |
| 06/12/2002 | EP1212455A1 Antisense modulation of telomeric repeat binding factor 1 expression |
| 06/12/2002 | EP1212446A2 Viral replicons and viruses dependent on inducing agents |
| 06/12/2002 | EP1212428A1 Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression |
| 06/12/2002 | EP1212423A2 Identification of the domain of plasmodium falciparum erythrocyte membrane protein 1 (pfemp1) that mediates adhesion to chondroitin sulfate a |
| 06/12/2002 | EP1212421A1 Gas1 polypeptides |
| 06/12/2002 | EP1212420A1 Conditional immortalisation of cells |
| 06/12/2002 | EP1212419A2 Polycyclic aromatic hydrocarbon induced molecules |
| 06/12/2002 | EP1212418A2 p193 PROTEINS AND NUCLEIC ACIDS, AND USES THEREOF |
| 06/12/2002 | EP1212416A2 Nucleic acid based modulators of gene expression |
| 06/12/2002 | EP1212415A1 Pgrp-l polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212407A1 Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212404A2 Isolation of muscle-derived stem cells and uses therefore |
| 06/12/2002 | EP1212362A2 Card proteins involved in cell death regulation |
| 06/12/2002 | EP1212359A1 Method for detecting the expression of an envelope protein of a human endogenous retrovirus and uses of a gene coding for said protein |
| 06/12/2002 | EP1212358A2 Synthetic papillomavirus genes optimized for expression in human cells |
| 06/12/2002 | EP1212355A2 Pharmaceutical compositions and methods of using secreted frizzled related protein |
| 06/12/2002 | EP1212344A1 B7-like polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212343A1 52 human secreted proteins |
| 06/12/2002 | EP1212340A1 29 human cancer associated proteins |
| 06/12/2002 | EP1212339A1 2'-o-acetamido modified monomers and oligomers |
| 06/12/2002 | EP1212331A1 28-epirapalogs |
| 06/12/2002 | EP1212087A1 Methods and compositions utilizing rad51 |
| 06/12/2002 | EP1212083A1 Oral recombinant lactobacilli vaccines |
| 06/12/2002 | EP1211931A1 A knockout mouse for the tumor suppressor gene anx7 |
| 06/12/2002 | EP1061941B1 A pharmaceutical composition containing ezrin mutated on tyrosine 353 |
| 06/12/2002 | EP0941123B1 Nucleic acid complexed with cationic polymer useful for gene therapy |
| 06/12/2002 | EP0939655B1 Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity |
| 06/12/2002 | EP0822941B1 Monoclonal antibodies against hiv-1 and vaccines made thereof |
| 06/12/2002 | EP0817864B1 Method for the diagnosis of crohn's disease and ulcerative colitis |
| 06/12/2002 | EP0802800B1 Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules |
| 06/12/2002 | EP0734391B1 Pna-dna-pna chimeric macromolecules |
| 06/12/2002 | EP0722452B1 Nf-at polypeptides and polynucleotides |
| 06/12/2002 | CN1353764A Method for selecting improved vectors |
| 06/12/2002 | CN1353754A Variants of TRAF2 which act as an inhibitor of TNF-alpha (TNF alpha) signaling pathway |
| 06/12/2002 | CN1353573A Anti-inflammatory therapy for inflammatory mediated infection |
| 06/12/2002 | CA2364392A1 Compound |
| 06/11/2002 | US6403765 Truncated Apaf-1 and methods of use thereof |
| 06/11/2002 | US6403559 C-kit ligand-based method for expanding peripheral blood cell levels |
| 06/11/2002 | US6403557 Fibroblast growth factor-13 |
| 06/11/2002 | US6403552 Ob receptor and methods for the diagnosis and treatment of body weight disorders |
| 06/11/2002 | US6403370 Generation an infection, reproduction, genetic engineering |
| 06/11/2002 | US6403360 Isolated nucleic acids |
| 06/11/2002 | US6403335 Amino acid sequence; promotes survival of mesencephalic cells; nervous system and degenerative disorders; parkinson*s disease; genetic engineering |
| 06/11/2002 | US6403318 Fatty acid synthase mRNA binding protein |
| 06/11/2002 | US6403310 Human inositol monophosphatase H1 |
| 06/11/2002 | US6403102 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 06/11/2002 | US6403091 Produced by the hybridoma having atcc accession no. hb 10916. |
| 06/11/2002 | US6403089 Inhibitors of fgl2; bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer, gastrointestinal diseases and fetal loss; monoclonal and polyclonal antibodies which bind to fgl2 and prevent fibrin |
| 06/11/2002 | US6403080 Methods of modulating an immune response to antigen, and cells for use in the method |
| 06/11/2002 | CA2152266C Methods for detection and treatment of individuals having abnormal cells expressing hla-a2/turyosinase peptide antigens |
| 06/11/2002 | CA2124218C Cytotoxic drug therapy |
| 06/11/2002 | CA2082390C Dna encoding human 5-ht1d receptors and uses thereof |
| 06/06/2002 | WO2002045431A2 Genetically engineered herpes virus for the treatment of cardiovascular disease |
| 06/06/2002 | WO2002044734A1 Method for diagnosing a tumor in a patient determining the concentration of pibf |
| 06/06/2002 | WO2002044424A1 Compositions, methods, apparatus and products comprising a stathmin/oncoprotein 18 sequence for detecting and treating cancer |
| 06/06/2002 | WO2002044419A2 Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| 06/06/2002 | WO2002044418A2 Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| 06/06/2002 | WO2002044406A2 Projection against mycobacterial infections |
| 06/06/2002 | WO2002044396A1 Photochemical internalization for delivery of molecules into the cytosol |
| 06/06/2002 | WO2002044395A1 Photochemical internalization for virus-mediated molecule delivery into the cyosol |
| 06/06/2002 | WO2002044394A2 Targetet retoviral vectors for cancer immunotherapy |
| 06/06/2002 | WO2002044393A1 Recombinant viral and non-viral vectors containing the human urokinase plasminogen activator gene and its utilization in the treatment of various types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars |
| 06/06/2002 | WO2002044384A2 T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy |
| 06/06/2002 | WO2002044382A1 Cytokine-like proteins |
| 06/06/2002 | WO2002044381A2 Human vno receptor (r1) |
| 06/06/2002 | WO2002044380A2 Master bone formation transcription factor: compositions and methods of use |
| 06/06/2002 | WO2002044379A2 Transforming growth factor-beta-related molecules and uses thereof |
| 06/06/2002 | WO2002044374A2 Flea gaba receptor subunit nucleic acid molecules, proteins and uses thereof |
| 06/06/2002 | WO2002044371A1 Human protooncogene and protein encoded therein |
| 06/06/2002 | WO2002044370A1 Human cervical cancer 2 protooncogene and protein encoded therein |
| 06/06/2002 | WO2002044369A1 Novel human chloride channel |
| 06/06/2002 | WO2002044366A2 Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379 |
| 06/06/2002 | WO2002044347A1 A virus which can express tumor angiostatin factor with high efficiency in specific tumor cells and the use of it |
| 06/06/2002 | WO2002044334A2 Recombinant rsv virus expression systems and vaccines |
| 06/06/2002 | WO2002044331A2 Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer |
| 06/06/2002 | WO2002044321A2 Rna interference mediating small rna molecules |
| 06/06/2002 | WO2002044320A2 Human elongase genes and uses thereof |
| 06/06/2002 | WO2002043774A2 Compositions and therapeutical use of polynucleotides encoding tcrs |
| 06/06/2002 | WO2002043769A2 Neutral and anionic colloidal particles for gene delivery |
| 06/06/2002 | WO2002043741A2 Methylenetetrahydrofolate reductase inhibitors and use thereof |
| 06/06/2002 | WO2002043570A2 METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES |
| 06/06/2002 | WO2002024148A3 Method or treatment of tumors using transforming growth factor-alpha |
| 06/06/2002 | WO2002005843A3 Human rrp sequences and methods of use |
| 06/06/2002 | WO2002002606A3 Immunisation against chlamydia pneumoniae |
| 06/06/2002 | WO2002000906A3 Replication deficient adenoviral tnf vector |
| 06/06/2002 | WO2001088116A9 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods |
| 06/06/2002 | WO2001083716A3 Immortalized lines of endothelial brain cells and therapeutic application thereof |
| 06/06/2002 | WO2001080840A3 Cytotoxic agents comprising single-stranded and/or looped dna |
| 06/06/2002 | WO2001079442A3 Albumin fusion proteins |